Study of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03669952|
Recruitment Status : Completed
First Posted : September 13, 2018
Last Update Posted : September 17, 2018
|Condition or disease||Intervention/treatment|
|Outcome of Breast Cancer||Other: None intervention|
Type of study:
A prospective observational longitudinal study was performed on patients who had undergone curative surgery for primary invasive breast cancer between 2010 and 2015. The study was performed in a single breast pathology unit [Alt Penedés hospital and Sant Camil hospital(GAP)]. Only patients with a definitive histopathology-based diagnostic of ductal carcinoma were included. Patients diagnosed with metastasis were excluded. Patients with bilateral breast cancer were included as two independent study cases.
Sample size calculation: 191. A total of 464 patients were included in the study. IDC was present in 221 patients (47.6%) and IDC + DCIS was present in 243 patients (52.4%).
Data collected included clinical characteristics (age, laterality and clinical symptoms at the time of diagnostic), histopathological information (tumor size, tumor grade, hormone receptors, nodal status, HER-2 mutation (erb-b2 receptor tyrosine kinase 2), number of ki67, presence and percentage of DCIS, grade of DCIS, and surrogate subtype) and surgical procedure performed.
Tumor histopathology and the number of lymph nodes involved were evaluated by routine hematoxylin-eosin (H&E) staining. The histological response to chemotherapy was assessed according to Miller-Payne criteria of grading (MPG) and Residual Disease in Breast and Nodes (RDBN).
The percentage of DCIS and its grade (classified as low, intermediate or high) was measured by two independent pathologists.
Quantitative data are shown as the median or mean of values and their variability is expressed as the range or standard deviation (SD), as specified for each analysis. Qualitative data are shown as absolute values or percentages. The incidence was used as a measure of frequency and the relative risk as a measure of association between independent groups.
The study of the normality of quantitative variables was done applying the Kolmogorov-Smirnov or the Shapiro-Wilk tests, as indicated for each analysis. For significance assessment of quantitative data, unpaired Student's T-test or two-tailed Mann-Whitney U test was applied, as specified for each analysis. For significance assessment of qualitative data, Fisher's exact test or Chi-squared test was applied. For the analysis of more than two groups, one-way ANOVA and Tukey's range test for post hoc pairwise comparison of groups, or Kruskal-Wallis were used. Survival was analyzed with the Kaplan-Meier estimate and survival distributions compared with the Log-Rank test. Multivariate Cox proportional hazards regression model was used to simultaneously evaluate the effect of several factors on survival and mortality.
Statistical analysis was performed using the software SPSS® (Statistical Package for the Social Sciences) version 21.
The aim of the investigator's study is to compare the clinical and histopathological factors between patients with IDC or DCIS-associated IDC (IDC + DCIS) and find the prognostic factors associated to recurrence and mortality in each group.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||464 participants|
|Target Follow-Up Duration:||7 Years|
|Official Title:||Longitudinal Observational Study About the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer|
|Actual Study Start Date :||January 1, 2010|
|Actual Primary Completion Date :||December 31, 2015|
|Actual Study Completion Date :||December 31, 2015|
Invasive ductal carcinoma
Patients with Invasive ductal carcinoma
Other: None intervention
No interventions are realized, only observational study
- Recurrence [ Time Frame: Patients included between 2010 and 2015 will be follow up til January of 2018 with a mean follow up of 51.43 months ]Neoplasm metastasis, either local or distant recurrence of the invasive ductal carcinoma